Announcements Trials

Browse Landscape

Phase

Phase 3 1 Phase 1 1

Status

Active not recruiting 1

Sponsor Class

Study Type

Interventional 1

Sponsor

Conditions

Recurrence 1 Neoplasms 1

Interventions

Carboplatin 36 Cisplatin 32 pembrolizumab 30 Paclitaxel 29 Pemetrexed 22 Gemcitabine 21 Nivolumab 19 Dexamethasone 17 Rituximab 16 Fluorouracil 13 Docetaxel 13 durvalumab 12 Ipilimumab 12 Capecitabine 12 Cyclophosphamide 11 atezolizumab 10 130-nm albumin-bound paclitaxel 10 olaparib 9 Trastuzumab 9 Lenalidomide 9 Doxorubicin 9 Cytarabine 9 Bevacizumab 9 daratumumab 8 Oxaliplatin 8 Bortezomib 8 Vinorelbine 7 Prednisone 7 Leucovorin 7 venetoclax 6

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

Clinical Trials

1 trials

Recent Start date Enrollment

Phase 3 × Has announcements × dostarlimab × Clear all

NCT03981796 2025-09-03

RUBY

Tesaro, Inc.

Phase 3 Active not recruiting

785 enrolled 2 FDA

Neoplasms, Recurrence

Data powered by HemOnc (CC BY 4.0) Colophon ⚡